Komori
Business Alliances4534Mochida Pharmaceutical Co.,Ltd.Pharmaceuticals

Notice of the Execution of an Agreement for the Sale of Dienogest in South Korea and Thailand

Mochida Pharmaceutical entered into an agreement granting LG Chem exclusive rights to develop and sell dienogest in South Korea and Thailand. LG Chem will obtain marketing approval in both countries before launching the product.

Worth reading
51Recurring
Scored from 4 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

Business Alliances
4534Mochida Pharmaceutical Co.,Ltd.
Alliance partnerLG Chem, Ltd.
Details of the alliance
  1. 1

    With respect to dienogest, which Mochida Pharmaceutical sells in Japan for indications including endometriosis, Mochida Pharmaceutical will grant LG Chem exclusive rights to develop and sell the product in South Korea and Thailand.

  2. 2

    LG Chem will obtain marketing approval for the product in each country and sell it there.

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

About the partner
Business DescriptionOne of the world's leading chemical companies, with a diverse business portfolio spanning petrochemicals, advanced materials and life sciences. LG Chem Life Sciences, the life sciences division of LG Chem, is committed to developing and providing innovative pharmaceuticals across a broad range of therapeutic areas.
LocationSeoul, South Korea
Contract Date31 March 2026
Agreements reached under this partnership
ItemDetails
Name of alliance partnerLG Chem, Ltd.
Alliance partner's business activitiesOne of the world's leading chemical companies, with a diverse business portfolio spanning petrochemicals, advanced materials and life sciences. LG Chem Life Sciences, the life sciences division of LG Chem, is committed to developing and providing innovative pharmaceuticals across a broad range of therapeutic areas.
Alliance partner's locationSeoul, South Korea
Type of allianceBusiness Alliances
Details of the allianceWith respect to dienogest, which Mochida Pharmaceutical sells in Japan for indications including endometriosis, Mochida Pharmaceutical will grant LG Chem exclusive rights to develop and sell the product in South Korea and Thailand., LG Chem will obtain marketing approval for the product in each country and sell it there.
Contract Date31 March 2026
Items this document does not state (17)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionAlliance start dateShare Acquisition Date and Payment DateImpact on Business PerformanceChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Mochida Pharmaceutical has been considering expansion into overseas markets, and is launching this product overseas for the first time as part of its efforts to promote global expansion. The two companies stated that they will deliver the product to patients in South Korea and Thailand and contribute to improving their quality of life.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of the Execution of an Agreement for the Sale of Dienogest in South Korea and Thailand | Mochida Pharmaceutical Co.,Ltd. (4534) timely disclosure | Komori